Copyright
©The Author(s) 2023.
World J Clin Oncol. Dec 24, 2023; 14(12): 606-619
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Table 1 Baseline data of the patients with primary central nervous system lymphoma
Characteristic | |
Age, yr | 57 (27–81) |
Sex, n (%) | |
Male | 9 (47.4) |
Female | 10 (52.6) |
ECOG-PS ≥ 2, n (%) | 5 (26.3) |
Invasion of deep intracranial areas, n (%) | 16 (84.2) |
High CSF protein concentration (> 450 mg/L), n (%) | 11 (68.75)1 |
High LDH serum concentration (> 250 U/L), n (%) | 1 (5.3) |
IELSG risk score, n (%) | |
Low | 3 (18.75)1 |
Intermediate | 12 (75)1 |
High | 1 (6.25)1 |
Follow-up time (mo) | 14.7 (3.9–30) |
- Citation: Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619
- URL: https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i12.606